Organovo's Bioprinting More Than A 'Stupid Exercise'
- Misleading short pieces and a cooling sector have had a negative effect on Organovo's share price.
- Organovo's fully cellular bioprinting method provides crucial benefits over competing approaches. This will distinguish Organovo as a 3D bioprinting leader.
- Data that the company has released has been compelling enough to warrant contracts without third party validation and product launch.